Alvac-HIV vCP205: NIH's AIDS vaccine evaluation group began a Phase I trial in 76 adults at low risk of HIV infection, with half of the volunteers required to h

Pasteur-Merieux/Connaught, Swiftwater, Penn. Product: Alvac-HIV vCP205, weakened canarypox virus-based HIV vaccine bearing a core protein, a surface protein, and a viral enzyme that are made into ps...